Skip Nav Destination
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
Issue Archive
Table of Contents
BLOOD COMMENTARIES
PLENARY PAPER
BLOOD SPOTLIGHT
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Clinical Trials & Observations
Susan O’Brien,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie Blum,Jeff Sharman,William Wierda,Jeffrey Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Ying Luan,Danelle F. James,Alvina D. Chu,John C. Byrd
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments
Sung-Yup Cho,Chang Ohk Sung,Jeesoo Chae,Jieun Lee,Deukchae Na,Wonyoung Kang,Jinjoo Kang,Seoyeon Min,Ahra Lee,Eunhye Kwak,Jooyoung Kim,Boram Choi,Hyunsoo Kim,Jeffrey H. Chuang,Hyo-Kyung Pak,Chan-Sik Park,Sanghui Park,Young Hyeh Ko,Dakeun Lee,Jin Roh,Min-Sun Cho,Seongyeol Park,Young Seok Ju,Yun-Suhk Suh,Seong-Ho Kong,Hyuk-Joon Lee,James Keck,Jacques Banchereau,Edison T. Liu,Woo-Ho Kim,Hansoo Park,Han-Kwang Yang,Jong-Il Kim,Charles Lee
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Clinical Trials & Observations
Brief Report
David Ghez,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Anne Calleja,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Caroline Protin,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Marine Baron,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Marie-Pierre Ledoux,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Gandhi Damaj,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Mathieu Dupont,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Brigitte Dreyfus,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Emmanuelle Ferrant,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Charles Herbaux,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Kamel Laribi,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Ronan Le Calloch,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Marion Malphettes,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Franciane Paul,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Laetitia Souchet,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Malgorzata Truchan-Graczyk,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Karen Delavigne,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Caroline Dartigeas,on behalf on the French Innovative Leukemia Organization (FILO) CLL group,Loïc Ysebaert,on behalf on the French Innovative Leukemia Organization (FILO) CLL group
RED CELLS, IRON, AND ERYTHROPOIESIS
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Chiara Antoniani,Vasco Meneghini,Annalisa Lattanzi,Tristan Felix,Oriana Romano,Elisa Magrin,Leslie Weber,Giulia Pavani,Sara El Hoss,Ryo Kurita,Yukio Nakamura,Thomas J. Cradick,Ante S. Lundberg,Matthew Porteus,Mario Amendola,Wassim El Nemer,Marina Cavazzana,Fulvio Mavilio,Annarita Miccio
TRANSPLANTATION
LETTERS TO BLOOD
Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
Clinical Trials & Observations
Sabrina Giammarco,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Régis Peffault de Latour,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Simona Sica,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Carlo Dufour,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Gerard Socie,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Jakob Passweg,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Nicolaus Kröger,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Eefke Petersen,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Maria Teresa Van Lint,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Rosi Oneto,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Alessio Signori,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party,Andrea Bacigalupo,for the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party
BLOOD WORK
-
Cover Image
Cover Image
Confocal reflection image of a Myo1f−/− neutrophil in a meshwork of collagen fibers unable to squeeze the nucleus through narrow pores that specifically hamper migration in 3-dimensional environments. The image shows the architecture of the collagen gel and the cell body of the neutrophil. See the article by Salvermoser et al on page 1887.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals